[go: up one dir, main page]

DE60318583D1 - N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung - Google Patents

N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung

Info

Publication number
DE60318583D1
DE60318583D1 DE60318583T DE60318583T DE60318583D1 DE 60318583 D1 DE60318583 D1 DE 60318583D1 DE 60318583 T DE60318583 T DE 60318583T DE 60318583 T DE60318583 T DE 60318583T DE 60318583 D1 DE60318583 D1 DE 60318583D1
Authority
DE
Germany
Prior art keywords
optionally substituted
äphenyl
methylubenzamide
piperidin
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60318583T
Other languages
English (en)
Other versions
DE60318583T2 (de
Inventor
Gihad Dargazanli
Genevieve Estenne-Bouhtou
Benoit Marabout
Pierre Roger
Mireille Sevrin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Application granted granted Critical
Publication of DE60318583D1 publication Critical patent/DE60318583D1/de
Publication of DE60318583T2 publication Critical patent/DE60318583T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60318583T 2002-07-29 2003-07-25 N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung Expired - Lifetime DE60318583T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0209588 2002-07-29
FR0209588A FR2842804B1 (fr) 2002-07-29 2002-07-29 Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
PCT/FR2003/002356 WO2004013101A2 (fr) 2002-07-29 2003-07-25 Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
DE60318583D1 true DE60318583D1 (de) 2008-02-21
DE60318583T2 DE60318583T2 (de) 2009-01-08

Family

ID=30011556

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60318583T Expired - Lifetime DE60318583T2 (de) 2002-07-29 2003-07-25 N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung

Country Status (9)

Country Link
US (2) US7205319B2 (de)
EP (1) EP1527048B1 (de)
JP (1) JP4488891B2 (de)
AT (1) ATE383338T1 (de)
AU (1) AU2003273475A1 (de)
DE (1) DE60318583T2 (de)
ES (1) ES2297205T3 (de)
FR (1) FR2842804B1 (de)
WO (1) WO2004013101A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2861071B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) * 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861070B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
AU2006205796B2 (en) * 2005-01-14 2010-09-02 Merck Sharp & Dohme B.V. Glycine reuptake inhibitors for treating drug and alcohol dependence
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
WO2009024611A2 (en) 2007-08-22 2009-02-26 Abbott Gmbh & Co. Kg 4-benzylaminoquinolines, pharmaceutical compositions containing them and their use
EP2527328A1 (de) 2008-04-01 2012-11-28 Abbott GmbH & Co. KG Tetrahydroisochinoline, pharmazeutische Zusammensetzungen damit und deren therapeutische Verwendung
WO2010087761A1 (en) * 2009-01-28 2010-08-05 Astrazeneca Ab 2-aza-bicyclo[2.2.2]octane compounds and uses thereof
TW201038569A (en) 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
CA2755526A1 (fr) * 2009-03-16 2010-09-23 Sanofi Derives de n-[(2-aza-bicyclo[2.1.1]hex-1-yl)-aryl-methyl]-heterobenzamide, leur preparation et leur application en therapeutique
FR2943056A1 (fr) * 2009-03-16 2010-09-17 Sanofi Aventis Derives de n-°2-aza-bicyclo°2.1.1!hex-1-yl)-aryl-methyl!- heterobenzamide, leur preparation et leur application en therapeutique
FR2944284A1 (fr) * 2009-04-14 2010-10-15 Sanofi Aventis Derives de n-°7-aza-bicyclo°2.2.1!hept-1-yl)-aryl-methyl! -benzamide, leur preparation et leur application en therapeutique
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2736329A4 (de) * 2011-07-29 2015-03-25 Tempero Pharmaceuticals Inc Verbindungen und verfahren
WO2013020930A1 (en) 2011-08-05 2013-02-14 Abbott Gmbh & Co. Kg Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2780328A1 (de) 2011-11-18 2014-09-24 Abbvie Deutschland GmbH & Co. KG N-substituierte aminobenzocyclohepten-, aminotetralin-, aminoindan- und phenylalkylaminderivate, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische verwendung
FR2983197B1 (fr) * 2011-11-29 2014-07-25 Assist Publ Hopitaux De Paris Utilisation de phacetoperane pour traiter un trouble deficit de l'attention hyperactivite
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2016004936A (es) 2013-10-17 2016-12-20 Abbvie Deutschland Derivados de aminocromano, aminotiocromano y amino-1,2,3,4-tetrahi droquinilina, composiciones farmaceuticas que los contienen, y su uso en terapia.
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
US9550754B2 (en) 2014-09-11 2017-01-24 AbbVie Deutschland GmbH & Co. KG 4,5-dihydropyrazole derivatives, pharmaceutical compositions containing them, and their use in therapy
US12178902B1 (en) 2020-01-12 2024-12-31 University Of Southern California Methods and compositions for fluid drainage by Piezo ion channel activation
CN114478360B (zh) * 2022-02-10 2023-08-15 江苏海洋大学 一种苯甲酰胺类衍生物及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2928835A (en) 1959-02-19 1960-03-15 Rhone Poulenc Sa New esters
US3336300A (en) 1965-04-13 1967-08-15 American Home Prod 1, 2, 3, 4-tetrahydro-5h-benzodiazepin-5-ones
US3801636A (en) 1971-08-13 1974-04-02 Abbott Lab 3,4,5-tri-substituted cinnamides
JPH02262562A (ja) 1988-10-20 1990-10-25 Ishihara Sangyo Kaisha Ltd イミダゾール系化合物
JP2765876B2 (ja) 1988-10-24 1998-06-18 科研製薬株式会社 ピリジルケトオキシムエーテル誘導体
US5254569A (en) * 1991-01-14 1993-10-19 The Du Pont Merck Pharmaceutical Company (Amidomethyl)nitrogen heterocyclic analgesics
JP3026845B2 (ja) * 1991-02-20 2000-03-27 日清製粉株式会社 ピペリジン誘導体
CZ284456B6 (cs) 1992-02-15 1998-12-16 Hoechst Aktiengesellschaft Aminosubstituované benzoylguanidiny, způsob jejich přípravy, jejich použití jako léčiv a léčivo, které je obsahuje
HUP0101281A3 (en) * 1998-03-06 2001-11-28 Janssen Pharmaceutica Nv Diphenyl-piperidine butanamides as glycine transport inhibitors, process for producing them, use of them for producing medicaments and the pharmaceutical compositions containing them
TWI243173B (en) * 1999-11-17 2005-11-11 Akzo Nobel Nv Spiro[2H-1-benzopyran-2,4'-piperidine] derivatives
CA2406652A1 (en) * 2000-04-20 2001-11-01 Nps Allelix Corp. Aminopiperidines for use as glyt-1 inhibitors
AR032653A1 (es) * 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
FR2838739B1 (fr) 2002-04-19 2004-05-28 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl)benzamide, leur preparation et leur application en therapeutique
JP2006516149A (ja) 2002-12-18 2006-06-22 エフ　エム　シー　コーポレーション Ｎ−（置換アリールメチル）−４−（二置換メチル）ピペリジン及びピリジン
FR2861076B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
FR2861074B1 (fr) 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861073B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
FR2861070B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(pyrrolidin-2-yl)methyl]benzamide et n-[(azepan-2-yl)phenylmethyl]benzamide, leur preparation et leur application en therapeutique
FR2861071B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
AU2006235400A1 (en) 2005-04-11 2006-10-19 Yale University Method of treating schizophrenia prodrome
FR2906251B1 (fr) 2006-09-22 2008-11-07 Sanofi Aventis Sa Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
AU2003273475A8 (en) 2004-02-23
JP4488891B2 (ja) 2010-06-23
US7205319B2 (en) 2007-04-17
DE60318583T2 (de) 2009-01-08
WO2004013101A2 (fr) 2004-02-12
JP2005537293A (ja) 2005-12-08
US20050153963A1 (en) 2005-07-14
ATE383338T1 (de) 2008-01-15
FR2842804B1 (fr) 2004-09-03
EP1527048B1 (de) 2008-01-09
US20070155789A1 (en) 2007-07-05
FR2842804A1 (fr) 2004-01-30
US7951821B2 (en) 2011-05-31
ES2297205T3 (es) 2008-05-01
EP1527048A2 (de) 2005-05-04
AU2003273475A1 (en) 2004-02-23
WO2004013101A3 (fr) 2004-05-13

Similar Documents

Publication Publication Date Title
DE60318583D1 (de) N-äphenyl(piperidin-2-yl)methylübenzamid-derivate, verfahren zu deren herstellung und ihre therapeutische verwendung
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
RS20060317A (en) Derivatives of n-/phenyl(alkylpiperidine-2-yl)methyl/ benzamide, preparation method thereof and application of same in therapeutics
RS91404A (en) Derivatives of n-(phenyl(piperidin-2- yl)benzamide, the preparation method thereof and application of same in therapeutics
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
RS20060316A (en) Derivatives of n-/heteroaryl(piperidine-2-yl)methyl/ benzamide, preparation method and application of same in therapeutics
DE60103508D1 (de) Pyrrolopyrimidinon-derivate, verfahren zu ihrer herstellung und verwendung
WO2004048340A8 (en) Sinomenine and sinomenine compounds, synthesis and use
RS20060315A (en) Derivatives of n-/phenyl(pyrrolidine-2-yl) methyl/benzamide, and n- /(azepan-2-yl)phenylmethyl/benzamide, preparation method thereof and application of same in therapeutics
DE602004009200D1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
EP1775289A4 (de) Neue imidazolidinderivate
ATE402185T1 (de) Verfahren für fluorcytidinderivate
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
TW200420559A (en) Amine compounds and method for producing the same
ATE399755T1 (de) Aminoalkoholderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verwendung davon
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
MY140963A (en) Phenylpyridylpiperazine compounds
ATE502030T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren verwendung
RS20050018A (en) Acyloxypyrrolidine derivatives and use thereof as ligands of v1b or both v1b and v1a receptors
EA200401290A1 (ru) НЕКОТОРЫЕ ПРОИЗВОДНЫЕ 1-(D-ЦИКЛОПРОПИЛГЛИЦИНИЛ)-4-(ПИПЕРИДИН-4-ИЛ)ПИПЕРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ СЕРИНПРОТЕАЗЫ ФАКТОРА Xa
ATE234315T1 (de) Medikamente gegen trhombocytopenie
BR9812928A (pt) Novos derivados de 3-oxo-(2h) -1,2,4-triazina, processo de preparação de compostos quìmicos, e, composição farmacêutica
EA200100155A2 (ru) Новые производные 6-амино или 6-гидразиносульфонил-3-хинолинилфосфоновой кислоты, способ их получения и содержащие их фармацевтические композиции
TW200504159A (en) Monoazo compound and process for making same
EP1340753A4 (de) Carbamatderivate, verfahren zu deren herstellung und deren verwendung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition